Uremic malnutrition-inflammation syndrome in chronic renal disease: A pathobiologic entity

Journal of Renal Nutrition

Volumn 13, Issue 4, 2003, Pages 250-258

  Bamgbola, Fatai O ^a,b   Kaskel, Fredrick J ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; UREMIC TOXIN;

BLOOD VESSEL FUNCTION; CHRONIC KIDNEY DISEASE; ENDOTHELIUM; HUMAN; HYPERHOMOCYSTEINEMIA; IMMUNE DEFICIENCY; INFLAMMATION; MALNUTRITION; PATHOLOGY; REVIEW; UREMIA; VASCULAR DISEASE;

ANEMIA; ANIMALS; ARTERIOSCLEROSIS; CHRONIC DISEASE; ENDOTHELIAL CELLS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERHOMOCYSTEINEMIA; IMMUNE SYSTEM; IMMUNITY, CELLULAR; INFLAMMATION; MALNUTRITION; NITRIC OXIDE; OXIDATIVE STRESS; SYNDROME; UREMIA; ZINC;

EID: 1642417322     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/S1051-2276(03)00114-6     Document Type: Review

References (64)

1. Kopple J.D., Greene T., Chumlea W.C., et al. Relationship between nutritional status and glomerular filtration rate Results from the MDRD study. Kidney Int. 57:2000;1688-1703.
2. Aguilera A., Codoceo R., Bajo M.A., et al. Helicobacter pylori infection A new cause of anorexia in peritoneal dialysis patients. Perit Dial Int. 21:(Suppl 3):2001;S152-S156.
3. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease before dialysis. Semin Dial. 16:2003;101-105.
4. Lim J., Gasson C., Kaji D.M. Urea inhibits NaK2Cl cotransport in human erythrocytes. J Clin Invest. 96:1995;2126-2132.
5. Martin-Malo A., Carracedo J., Ramirez R., et al. Effect of uremia and dialysis modality on mononuclear cell apoptosis. J Am Soc Nephrol. 11:2000;936-942.
6. Cendroglo M., Jaber B.L., Balakrishnan V.S., et al. Neutrophil apoptosis and dysfunction in uremia. J Am Soc Nephrol. 10:1999;93-100.
7. Niwa T. 3-Deoxyglucosone Metabolism, analysis, biological activity, and clinical implication. J Chromatogr B Biomed Sci Appl. 731:1999;23-26.
8. Guo Z., Hou F., Zhang X., et al. Advanced glycation end products inhibit production of NO by human endothelial cells through activation of the p38 signal pathway. Zhonghua Yi Xue Za Zhi. 10:2002;1328-1331.
9. Schwedler S., Schinzel R., Vaith P., et al. Inflammation and advanced glycation end products in uremia Simple coexistence, potentiation or causal relationship? Kidney Int. 78:(Suppl 78):2001;S32-S326.
10. Aguilera A., Selgas R., Diez J.J., et al. Anorexia in end stage renal disease Pathophysiology and treatment. Expert Opin Pharmacother. 2:2001;1825-1838.
11. Mamoun A.H., Sodersten P., Anderstam B., et al. Evidence of splanchnic-brain signaling in inhibition of ingestive behavior by middle molecules. J Am Soc Nephrol. 10:1999;309-314.
12. O'Sullivan A.J., Lawson J.A., Chan M., et al. Body composition and energy metabolism in chronic renal insufficiency. Am J Kidney Dis. 39:2002;369-375.
13. Mitch W.E. Insights into the abnormalities of chronic renal disease attributed to malnutrition Pathophysiology of chronic renal failure and complications. J Am Soc Nephrol. 13:(Suppl 1):2002;S22-S27.
14. Odamaki M., Furuya R., Yoneyama T., et al. Association of serum leptin concentration with weight loss in chronic hemodialysis patients. Am J Kidney Dis. 33:1999;361-368.
15. Astrup A., Toubro S., Dalgaard L.T., et al. Impact of the v/v 55 polymorphism of the uncoupling protein 2 on 24-h energy expenditure and substrate oxidation. Int J Obes Relat Metab Disord. 23:1999;1030-1034.
16. Stevinkel P. The role of inflammation in the anaemia of end stage renal disease. Nephrol Dial Transplant. 16:2001;36-40.
17. Kong Q.Y., Wu X., Li J., et al. Loss of phospholipid asymmetry in red blood cells contributes to anemia in uremic patients. Adv Perit Dialysis. 17:2001;58-60.
18. Canestrari F., Galli F., Giorgini A., et al. Erythrocyte redox state in uremic anemia Effects of hemodialysis and relevance of glutathione metabolism. Acta Hematol. 91:1994;187-193.
19. Besarab A., Amin N., Ahsan M., et al. Optimization of epoietin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol. 11:2000;530-538.
20. Zima T. Trace elements in end stage renal disease Clinical implication of trace elements. Blood Purif. 17:1999;187-198.
21. D'Haese P.C. Aluminum, iron, lead, cadmium, copper, zinc, chromium, magnesium, strontium, and calcium content in bone of end-stage renal failure patients. 45:1999;1548-1556.
22. Prasad A.S., Bao B., Beck F.W., et al. Zinc activates NF-kappa B in HUT-78 cells. J Clin Med. 138:2001;250-256.
23. El Hendy H.A., Yousef M.I., Abo El-Naga N.I. Effect of dietary zinc deficiency on hematological and biochemical parameters and concentrations of zinc, copper, and iron in growing rats. Toxicology. 167:2001;163-170.
24. Jern N.A., Van Beber A.D., Gorman M.A., et al. The effects of zinc supplementation on serum zinc concentration and protein catabolic rate in hemodialysis patients. J Renal Nutr. 10:2000;148-153.
25. Candan F., Gultekin F., Candan F. Effect of vitamin C and zinc on osmotic fragility and lipid peroxidation in zinc deficient haemodialysis patients. Cell Biochem Funct. 20:2002;95-98.
26. O'Dell B.L. Role of zinc in plasma membrane function. J Nutr. 130:(Suppl 5S):2000;s1432-s1436.
27. Goral S. Levocarnitine and muscle metabolism in patients with end stage renal disease. J Ren Nutr. 8:1998;118-121.
28. Nikolaos S., George A., Telemachos T., et al. Effect of L-carnitine supplementation on red cell deformability in hemodialysis patients. Ren Fail. 22:2000;73-80.
29. Matsumato Y., Sato M., Ohashi H., et al. Effects of L-carnitine on cardiac morbidity in hemodialyzed patients. Am J Nephrol. 20:2000;201-207.
30. Roelfsema V., Clark R.G. The growth hormone and insulin-like growth factor axis Its manipulation for the benefit of growth disorders in renal failure. J Am Soc Nephrol. 12:2001;1297-1306.
31. Morris S.T., Jardine A.G. The vascular endothelium in chronic renal failure. J Nephrol. 13:2000;96-105.
32. Serradell M., Diaz-Ricart M., Cases A., et al. Uremic medium disturbs the hemostatic balance of cultured human endothelial cells. Thrombosis Haemostasis. 86:2001;1099-1105.
33. Kaysen G.A. The micro-inflammatory state in uremia Causes and potential consequences. J Am Soc Nephrol. 12:2001;1549-1557.
34. Stenvinkel P., Heimburger O., Tuck C.H., et al. Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int. 53:1998;1336-1342.
35. Schwedler S., Schinzel R., Vaith P., et al. Inflammation and advanced glycation end products in uremia Simple co-existence, potentiation or causal relationship? Kidney Int. 78:(Suppl 78):2001;S32-S36.
36. Drueke T.B., Khoa T.N., Massy Z.A., et al. Role of oxidized low-density lipoprotein in the atherosclerosis of uremia. Kidney Int. 78:(Suppl 78):2001;S114-S119.
37. 12 and folate influence plasma homocysteine in hemodialysis patients. Am J Kidney Dis. 39:2002;1032-1039.
38. Mc Gregor D.O., Dellow W.J., Lever M., et al. Dimethyl-glycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. Kidney Int. 59:2001;2267-2272.
39. Mezzano D., Pais E.O., Aranda E., et al. Inflammation, not hyperhomocysteinemia, is related to oxidative and hemostatic and endothelial dysfunction in uremia. Kidney Int. 60:2001;1844-1850.
40. Mendes Ribeiro A.C., Brunini T.M.C., Ellory J.C., et al. Abnormalities in L-arginine transport and nitric oxide biosynthesis in chronic renal and failure. Cardiovasc Res. 49:2001;697-712.
41. Aiello S., Noris M., Remuzzi G. Nitric oxide/L-arginine in uremia. Min Electrol Metabol. 25:1999;384-390.
42. Zhang R., Brennan M.L., Fu X., et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 286:2001;2136-2142.
43. Nikpoor B., Turecki G., Fournier C., et al. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J. 142:2001;336-339.
44. Raskova J., Czerwinski D.K., Shea S.M., et al. Cellular immunity and lymphocyte populations in developing uremia in the rat. J Exp Pathol. 2:1986;229-245.
45. Libetta C., Rampino T., Dal Canton A. Polarization of T-helper lymphocytes toward the Th2 phenotype in uremic patients. Am J Kidney Dis. 38:2001;286-295.
46. Girndt M., Sester U., Sester M., et al. Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlate to the uremia-associated immune defect. Kidney Int. 59:2001;1382-1389.
47. Gagnon R.F. Delayed-type hypersensitivity skin reaction in the chronically uremic mouse Influence of severity and duration of uremia on the development of response. Nephron. 43:1986;16-21.
48. Smogorzewski M.J., Massry S.G. Defects in B cell function and metabolism in uremia Role of parathyroid hormone. Kidney Int. 78:(Suppl 78):2001;S186-S189.
49. Martin-Malo A., Carracedo J., Ramirez R., et al. Effect of uremia and dialysis modality on mononuclear cell apoptosis. J Am Soc Nephrol. 11:2000;936-942.
50. Cendroglo M., Jaber B.L., Balakrishnan V.S., et al. Neutrophil apoptosis and dysfunction in uremia. J Am Soc Nephrol. 10:1999;93-100.
51. Cohen G., Rudnick M., Walter F., et al. Glucose modified proteins modulate essential functions and apoptosis of polymorphonuclear leukocytes. J Am Soc Nephrol. 12:2001;1264-1271.
52. Jaber B., Perianayagam M.C., Balakrishnan V.S., et al. Mechanisms of neutrophil apoptosis in uremia and relevance of the Fas (APO-1, CD95)/Fas ligand system. J Leucoc Biol. 69:2001;1006-1012.
53. Vanholder R., De Smet R., Waterloos M.A., et al. Mechanisms of uremic inhibition of phagocyte reactive species production characterization of the role of p-cresol. Kidney Int. 47:1995;510-517.
54. Hirayama A., Noronha-Dutra A.A., Gordge M.P., et al. Inhibition of neutrophil superoxide production by uremic concentrations of guanidine compounds. J Am Soc Nephrol. 11:2000;684-689.
55. Deicher R., Exner M., Cohen G., et al. Neutrophil beta (2)-microglobulin and lactoferrin content in renal failure patients. Am J Kidney Dis. 35:2000;1117-1126.
56. Haag-Weber M., Horl W.H. Are granulocyte inhibitory proteins contributing to enhanced susceptibility to infections in uraemia? Nephrol Dial Transplant. 11:(Suppl 2):1996;S98-S100.
57. Stenvinkel P., Wanner C., Metzger T., et al. Inflammation and to outcome in end-stage renal failure Does female gender constitute a survival advantage? Kidney Int. 62:2002;1791-1798.
58. Kimmel P.L., Phillips T.M., Simmens S.J., et al. Immunologic function and survival in hemodialysis patients. Kidney Int. 54:1998;236-244.
59. Memoli B., Postiglione L., Cianciaruso B., et al. Role of different dialysis membranes in the release of interleukin-6-soluble receptor in uremic patients. Kidney Int. 58:2002;417-424.
60. Girndt M., Kaul H., Sester U., et al. Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int. 62:2002;945-955.
61. Stenvinkel P., Heimburger O., Jogestrand T., et al. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients Association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis. 39:2002;274-282.
62. Kaizu Y., Kimura M., Yoneyama T., et al. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis. 31:1998;93-100.
63. Kato A., Odamaki M., Takita T., et al. Association between interleukin-6 and carotid atherosclerosis in hemodialysis patients. Kidney Int. 62:2002;945-955.
64. Moldawer L.L., Andersson C., Gelin J., et al. Regulation of food intake and hepatic protein synthesis by recombinant-derived cytokines. Am J Physiol. 254:1988;G450-G456.